Announcement • May 20
Health Catalyst, Inc., Annual General Meeting, Jul 16, 2026 Health Catalyst, Inc., Annual General Meeting, Jul 16, 2026. Announcement • May 03
Health Catalyst Appoints Steve Nelson to Its Board of Directors, Effective May 1, 2026 Health Catalyst, Inc. announced that Steve Nelson, Executive Vice President and President of Aetna, a CVS Health company, has been appointed to its Board of Directors, effective May 1, 2026. Nelson’s appointment follows the naming of Ben Albert as CEO and Justin Spencer as Chairman of the Board earlier this year, continuing a deliberate pattern of leadership moves designed to accelerate the company's transformation– executing on a single, coordinated strategy to help health systems address cost, clinical outcomes, and consumer experience as one imperative. In his current role at Aetna, a CVS Health company, Nelson has championed stronger provider partnerships and a less transactional approach to healthcare. Previously, he served as Chief Executive Officer of ChenMed and led Duly Health and Care, building and scaling delivery models where health outcomes, provider experience, cost discipline, clinical performance, and consumer engagement operated as a single integrated strategy. His earlier tenure as CEO of UnitedHealthcare, combined with other executive and board roles across both public and private healthcare organizations, gives him deep understanding on the forces shaping how health systems are reimbursed, evaluated, and held accountable. He brings to Health Catalyst's board a breadth of perspective deeply rooted in what health system clients need their intelligence partner to understand. Announcement • May 01
Health Catalyst, Inc. to Report Q1, 2026 Results on May 11, 2026 Health Catalyst, Inc. announced that they will report Q1, 2026 results After-Market on May 11, 2026 Major Estimate Revision • Mar 19
Consensus EPS estimates fall by 39% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$301.6m to US$282.0m. Losses expected to increase from US$0.55 per share to US$0.76. Healthcare Services industry in the US expected to see average net income growth of 21% next year. Consensus price target down from US$3.88 to US$2.09. Share price fell 32% to US$1.22 over the past week. New Risk • Mar 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$34m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Price Target Changed • Mar 13
Price target decreased by 28% to US$2.84 Down from US$3.94, the current price target is an average from 8 analysts. New target price is 115% above last closing price of US$1.32. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$0.71 next year compared to a net loss per share of US$2.55 last year. Reported Earnings • Mar 13
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$2.55 loss per share (further deteriorated from US$1.16 loss in FY 2024). Revenue: US$311.1m (up 1.5% from FY 2024). Net loss: US$178.0m (loss widened 156% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 93%. Revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Healthcare Services industry in the US are expected to grow by 10%. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Announcement • Mar 02
Health Catalyst, Inc. to Report Q4, 2025 Results on Mar 12, 2026 Health Catalyst, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026 Board Change • Mar 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & Director Ben Albert was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • Jan 30
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$128k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$34m net loss in 3 years). Significant insider selling over the past 3 months (US$128k sold). Announcement • Jan 24
Health Catalyst, Inc. Announces Executive Changes Health Catalyst, Inc. announced that on January 20, 2026, the Board of Directors determined that Kevin Freeman will cease to serve as the Chief Commercial Officer of the Company on February 1, 2026. In order to enable a smooth transition of his prior responsibilities as Chief Commercial Officer, the Company and Mr. Freeman anticipate entering into a separation agreement and then anticipate entering into an independent contractor agreement pursuant to which Mr. Freeman will serve as a senior advisor starting February 2, 2026. Recent Insider Transactions Derivative • Dec 14
Insider notifies of intention to sell stock Benjamin Landry intends to sell 27k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of December. If the sale is conducted around the recent share price of US$2.69, it would amount to US$74k. Since March 2025, Benjamin has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively bought US$767k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions • Dec 10
Independent Director recently sold US$128k worth of stock On the 4th of December, Julie Larson-Green sold around 48k shares on-market at roughly US$2.67 per share. This transaction amounted to 56% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$767k more than they sold in the last 12 months. Recent Insider Transactions Derivative • Dec 03
CEO & Director notifies of intention to sell stock Daniel Burton intends to sell 56k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of December. If the sale is conducted around the recent share price of US$2.90, it would amount to US$162k. For the year to December 2018, Daniel's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Daniel's direct individual holding has increased from 1.00m shares to 1.04m. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Announcement • Dec 02
Health Catalyst, Inc. Announces Board Changes Health Catalyst, Inc. announced that Matt Arens, CEO and Founder of First Light Asset Management, LLC, has been appointed to serve as a member of Health Catalyst's board of directors, effective December 1, 2025. Since entering the investment field nearly 30 years ago, Mr. Arens has focused on identifying healthcare companies presenting unique opportunities for growth. He has managed dedicated healthcare portfolios for more than 15 years and serves as senior portfolio manager across all First Light investment strategies. The firm's longest-running separately managed account strategy was ranked the number one U.S. small-cap growth strategy for the period spanning its inception in September 2008 through the period ended September 30, 2025 (ranking by PSN/Informa). Prior to founding First Light in 2013, Mr. Arens was president and senior portfolio manager at Kopp Investment Advisors. While at Kopp, he served as the sole portfolio manager for the firm's healthcare-focused investment strategy. Mr. Arens graduated from Purdue University with a Bachelor of Science in financial planning. The company also announced that Matthew Kolb, who has served as Health Catalyst director since 2023, will not stand for re-election at the company's 2026 annual meeting. Major Estimate Revision • Nov 17
Consensus EPS estimates fall by 16% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$1.14 to -US$1.32 per share. Revenue forecast unchanged at US$310.3m. Healthcare Services industry in the US expected to see average net income growth of 43% next year. Consensus price target down from US$4.33 to US$3.94. Share price fell 21% to US$2.27 over the past week. Reported Earnings • Nov 12
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$0.32 loss per share (further deteriorated from US$0.24 loss in 3Q 2024). Revenue: US$76.3m (flat on 3Q 2024). Net loss: US$22.2m (loss widened 51% from 3Q 2024). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 75%. Revenue is forecast to stay flat during the next 3 years compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Announcement • Nov 11
Health Catalyst, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2025 Health Catalyst, Inc. provided earnings guidance for the fourth quarter of 2025 and full year 2025. For the fourth quarter of 2025, the company expects Total revenue of approximately $73.5 million.
For the full year of 2025, the company expects Total revenue of approximately $310 million. Announcement • Oct 21
Health Catalyst, Inc. to Report Q3, 2025 Results on Nov 10, 2025 Health Catalyst, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 10, 2025 Announcement • Sep 11
Health Catalyst, Inc. Announces Appointment of Ben Albert as President and Chief Operating Officer Health Catalyst, Inc. announced that Ben Albert has been appointed as President and Chief Operating Officer. Albert served as the Chief Executive Officer & Co-Founder of Upfront Healthcare Services, Inc. until it was acquired by Health Catalyst in January, and has continued to oversee the business since the acquisition. An established entrepreneur, Albert has spent more than 25 years building and leading healthcare organizations that deliver a compelling value proposition to successfully activate patients, while improving clinical, financial, and operational outcomes. As President and COO, Albert will provide the Health Catalyst team essential day-to-day leadership, guiding operations through this pivotal phase for the company while positioning the organization for long-term success. Senior leaders in Product Engineering, Technology Delivery and Support, Growth, Operations, Finance, and Corporate Strategy will report to Albert. Albert will work in close partnership with Health Catalyst CEO Dan Burton, who has previously announced that he will retire from his role as CEO effective June 2026. The Board is confident that this partnership will provide clear accountability for day-to-day operations, alignment, continuity, and stability. Burton remains engaged as CEO and focused on investor relationships and customer growth in advance of his previously announced retirement while the Board continues its search for the next CEO. As Albert steps into the President and COO role, Dan LeSueur will complete his full-time service with Health Catalyst and is expected to transition to a part-time advisory role to support Albert and Health Catalyst in this transition. Price Target Changed • Aug 29
Price target decreased by 15% to US$4.56 Down from US$5.33, the current price target is an average from 9 analysts. New target price is 34% above last closing price of US$3.39. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$1.14 next year compared to a net loss per share of US$1.15 last year. Announcement • Aug 27
Health Catalyst Announces Upfront: Market Insights on Salesforce AppExchange Health Catalyst, Inc. announced that Upfront by Health Catalyst ("Upfront") has launched Market Insights on Salesforce AppExchange, a leading enterprise marketplace for partner apps and experts. With Market Insights, clients can guide more patients to care using actionable consumer insights that drive content optimizations, power intelligent user journeys, and improve campaign performance. Upfront's AppExchange listing makes its exclusive Market Insights available to a wider audience, layering these insights directly into existing Salesforce workflows without the need for additional tools or manpower. Now, healthcare enterprises can more deeply understand their populations, automatically segment contact lists based on psychographics, and build highly targeted journeys with content that speaks to each patient's unique motivateators. New Risk • Aug 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$25m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Major Estimate Revision • Aug 15
Consensus EPS estimates fall by 17% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$334.3m to US$318.2m. Losses expected to increase from US$0.90 per share to US$1.05. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$6.89 to US$5.33. Share price rose 3.2% to US$2.92 over the past week. Price Target Changed • Aug 10
Price target decreased by 20% to US$5.78 Down from US$7.20, the current price target is an average from 9 analysts. New target price is 104% above last closing price of US$2.83. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$1.15 last year. Reported Earnings • Aug 08
Second quarter 2025 earnings: EPS misses analyst expectations Second quarter 2025 results: US$0.59 loss per share (further deteriorated from US$0.23 loss in 2Q 2024). Revenue: US$80.7m (up 6.3% from 2Q 2024). Net loss: US$41.0m (loss widened 203% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 155%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Announcement • Jul 17
Health Catalyst, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Health Catalyst, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Announcement • Jul 02
Health Catalyst, Inc. Announces the Release of 10 AI-Integrated Data Toolkits on Databricks Marketplace Health Catalyst, Inc. announced it is listing 10 AI-integrated data toolkits on Databricks Marketplace, an open marketplace for data, analytics and AI underpinned by the Databricks Data Intelligence Platform. These data toolkits, which can be securely shared via Delta Sharing, are purpose-built for some of healthcare's most pressing challenges and provide healthcare organizations with access to actionable, outcomes-focused resources that kickstart their measurable improvement journeys at no cost. The toolkits will enable healthcare organizations to trial use cases, experience the value of Health Catalyst's deep domain expertise firsthand, and offer the opportunity to enter into a meaningful partnership to further their data-informed healthcare improvement. The availability of these toolkits on the Databricks Marketplace, leveraging Delta Sharing, ensures that these toolkits can be securely and efficiently accessed by healthcare organizations, regardless of their computing platform, without the need for data replication. The release of these data toolkits on Datibricks Marketplace is the latest result of the partnership between Health Catalyst and Databricks. In January, Health Catalyst entered a partnership with Databricks to advance healthcare data sharing and analytics with a configurable solution designed specifically for healthcare organizations. These data toolkits are equipped with advanced machine learning (ML) models, including limited versions of Health Catalyst's Healthcare.AI and large language models (LLM) capabilities, designed to help health systems drive significant improvements and achieve better outcomes across key areas, including: Predicting hospital readmissions; Reducing avoidable emergency department (ED) visits; Improving at-risk HEDIS scores; Enabling intelligent patient attribution matching; Detecting barriers to patient access; Forecasting hospital patient throughput; Reducing inpatient length of stay; Optimizing surgical outcomes; Forecasting next month's patient survey scores; Detecting anomalies in patient satisfaction. These reusable resources remove common barriers to measurable improvement by giving users a ready-to-run framework, rather than starting from scratch. Teams can reference the demo data and immediately use the book to explore key questions. At their fingertips is a prebuilt methodology that guides them through advanced analytics for driving interventions, such as using generative AI to customize post-discharge care instructions based on a patient's readmission risk. By opening access to these tools, Health Catalyst aims to make high-impact, measurable improvement more attainable and support a more efficient, informed approach to healthcare delivery. This latest initiative underscores Health Catalyst's continued commitment to making the path to measurable improvement more accessible across the healthcare community. It follows the April launch of Health Catalyst Ignite Spark™?, a tailored analytics solution built specifically for community health systems, regional hospitals, and multi-site practices, bringing enterprise-grade capabilities to teams with leaner resources. Together, these efforts reflect a broader focus on removing barriers and enabling organizations of all sizes to turn data into sustained action. Price Target Changed • May 29
Price target decreased by 7.9% to US$7.45 Down from US$8.09, the current price target is an average from 11 analysts. New target price is 99% above last closing price of US$3.74. Stock is down 43% over the past year. The company is forecast to post a net loss per share of US$0.90 next year compared to a net loss per share of US$1.15 last year. Announcement • May 09
Health Catalyst, Inc., Annual General Meeting, Jul 09, 2025 Health Catalyst, Inc., Annual General Meeting, Jul 09, 2025. Reported Earnings • May 09
First quarter 2025 earnings: EPS misses analyst expectations First quarter 2025 results: US$0.35 loss per share. Revenue: US$79.4m (up 6.3% from 1Q 2024). Net loss: US$23.7m (loss widened 15% from 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 13%. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Announcement • May 08
Health Catalyst, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025 Health Catalyst, Inc. provided earnings guidance for the second quarter and full year 2025. For the second quarter, the company expects total revenue of approximately $80.5 million.
For the full year, the company expects total revenue of approximately $335 million. Announcement • Apr 17
Health Catalyst, Inc. to Report Q1, 2025 Results on May 07, 2025 Health Catalyst, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Announcement • Apr 10
Health Catalyst Releases Data and Analytics Solution Designed for Community, Regional, and Specialty Health Systems: Health Catalyst Ignite Spark Health Catalyst, Inc. announced the launch of Health Catalyst Ignite Spark, a tailored data and analytics solution built for community health systems, regional hospitals, and multi-site practices. Smaller community health systems across the U.S. are navigating shrinking margins, policy uncertainty, and rising pressure to deliver more with less. Ignite Spark is company's answer--a nimble, flexible, and accessible data and analytics solution purpose-built to meet this moment. Ignite Spark is designed to be foundational, to seamlessly complement existing systems, and to provide enterprise-grade analytics for teams with lean resources. Delivers trusted insights from existing data without added complexity or disruption, empowering teams to act with confidence. Streamlines access to critical insights with intuitive self-service tools, smart data pathways, and fewer vendors handoffs--reducing cost and operational friction. Optimizes decision-making by leveraging AI-driven insights, delivering smarter, faster, and more informed choices for healthcare teams. Adapts to environment with a purpose-built app layer, offering the flexibility to evolve with strategy, scale across sites, and meet changing organizational needs. Ignite Spark ingests and normalizes data from multiple sources, centralizes governance, and empowers frontline teams with self-service access to actionable insights--all while reducing IT burden and unnecessary cost. Ignite Spark breaks down the cost, access, and expertise barrier; through this streamlined solution, regional hospital networks, primary care networks, urgent care centers, and specialty practices can drive data-informed clinical, revenue performance, and cost control improvement. Major Estimate Revision • Mar 05
Consensus EPS estimates fall by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.746 to -US$0.843 per share. Revenue forecast unchanged at US$334.6m. Healthcare Services industry in the US expected to see average net income growth of 26% next year. Consensus price target down from US$9.79 to US$8.67. Share price fell 7.9% to US$4.55 over the past week. Recent Insider Transactions Derivative • Mar 04
CEO & Director notifies of intention to sell stock Daniel Burton intends to sell 34k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of March. If the sale is conducted around the recent share price of US$4.58, it would amount to US$154k. Since March 2024, Daniel's direct individual holding has increased from 835.87k shares to 1.00m. There have been no trades via on-market transactions or options from company insiders in the last 12 months. New Risk • Feb 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Price Target Changed • Feb 27
Price target decreased by 12% to US$8.96 Down from US$10.13, the current price target is an average from 12 analysts. New target price is 104% above last closing price of US$4.39. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$1.15 last year. Reported Earnings • Feb 27
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: US$1.16 loss per share (improved from US$2.09 loss in FY 2023). Revenue: US$306.6m (up 3.6% from FY 2023). Net loss: US$69.5m (loss narrowed 41% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Announcement • Feb 05
Health Catalyst, Inc. to Report Q4, 2024 Results on Feb 26, 2025 Health Catalyst, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 26, 2025 Price Target Changed • Jan 29
Price target decreased by 8.0% to US$10.13 Down from US$11.00, the current price target is an average from 12 analysts. New target price is 80% above last closing price of US$5.63. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$1.04 next year compared to a net loss per share of US$2.09 last year. Price Target Changed • Jan 22
Price target decreased by 7.8% to US$10.29 Down from US$11.17, the current price target is an average from 12 analysts. New target price is 83% above last closing price of US$5.61. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$1.04 next year compared to a net loss per share of US$2.09 last year. Announcement • Jan 13
Health Catalyst, Inc. (NasdaqGS:HCAT) has signed a definitive agreement to acquire Upfront Healthcare Services, Inc. for approximately $112 million. Health Catalyst, Inc. (NasdaqGS:HCAT) has signed a definitive agreement to acquire Upfront Healthcare Services, Inc. for approximately $112 million on January 10, 2025. Upon consummation of the transaction contemplated by the Merger Agreement, all outstanding shares of Upfront capital stock, warrants and options to purchase Upfront capital stock will be cancelled in exchange for the right to receive: (i) consideration of approximately $86 million, net of cash on hand (“Closing Consideration”), subject to customary transaction adjustments set forth in the Merger Agreement, and (ii) potential additional aggregate consideration of approximately $33.4 million (the “Earn-Out”) subject to the achievement of certain earn-out performance targets measured as of December 31, 2026 (the “Measurement Date”). Closing Consideration will consist of approximately $41.5 million of cash, net of cash on hand, and approximately 5,753,814 shares (“Closing Stock Consideration”) of newly issued shares of the Company’s common stock, par value $0.001 per share (“Common Stock”). If achieved, any Earn-Out will be comprised of 37.5% cash and 62.5% shares of Common Stock (such shares of Common Stock, together with the Closing Stock Consideration, the “Stock Consideration”), with the maximum Earn-Out resulting in the payment of approximately $12.5 million in cash and approximately 2,699,121 shares of Common Stock.
The transaction is subject to approval by regulatory board / committee, approval of offer by target shareholders and subject to antitrust regulations. The Closing is expected to occur during the Company’s quarter ending March 31, 2025. Recent Insider Transactions Derivative • Dec 03
CEO & Director notifies of intention to sell stock Daniel Burton intends to sell 31k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of December. If the sale is conducted around the recent share price of US$8.97, it would amount to US$278k. Since March 2024, Daniel's direct individual holding has increased from 835.87k shares to 863.72k. There has only been one transaction (US$205k purchase) from insiders over the last 12 months. Announcement • Nov 20
Health Catalyst Launches AI-Enabled Cyber Protection Product for Healthcare Health Catalyst, Inc. announced the launch of an AI-powered version of BluePrint Protect™? from Intraprise Health, LLC ("Intraprise Health"), a platform that empowers healthcare organizations to screen and identify risks related to cybersecurity threats through third parties. On November 6, 2024, Health Catalyst announced it signed a definitive agreement to acquire Intraprise Health, a tech-enabled cybersecurity provider offering an end-to-end cybersecurity risk management platform and services to protect healthcare clients from cyberattacks and manage follow-on liability in the event of an incident. As cyberattacks increase in speed and sophistication, a typical hospital system increasingly grapples with the burden of assessing security risks related to their hundreds of vendors. This vetting and management process can be difficult, costly, and time-consuming. BluePrint Protect's newest capability, AI-powered third-party risk manager, was introduced to streamline these assessments by automating the generation, distribution, and tracking of vendor security information. It leverages Generative AI to evaluate vendor responses and supporting evidence while flagging and prioritizing risks significantly faster than traditional methods. This efficiency not only saves organizations time and money but also enables them to identify and address risks more quickly, which can help reduce the likelihood of a breach. BluePrint Protect's capabilities include: Automated Risk Workflows: BluePrint Protect streamlines third-party risk assessments and reduces manual efforts through AI-generated questionnaires and evidence evaluation with automated follow-ups. Enhanced Risk Visibility: BluePrint Protect provides intuitive dashboards that deliver critical insights into vulnerabilities, helping healthcare organizations respond faster to potential risks. Customizable and Cost-Effective: Health systems can tailor the solution to meet specific needs. BluePrint Protect also eliminates the need for some other security products, scales existing teams, and simplifies operations. Compatibility: The platform maintains compatibility and interoperability with third-party products and other risk assessment tools, enabling the efficient consolidation of findings from multiple sources and prior engagements. Reported Earnings • Nov 07
Third quarter 2024 earnings: EPS misses analyst expectations Third quarter 2024 results: US$0.24 loss per share (improved from US$0.39 loss in 3Q 2023). Revenue: US$76.4m (up 3.5% from 3Q 2023). Net loss: US$14.7m (loss narrowed 33% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.5%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Recent Insider Transactions Derivative • Sep 06
Chief Operating Officer notifies of intention to sell stock Daniel LeSueur intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of September. If the sale is conducted around the recent share price of US$7.25, it would amount to US$59k. Since March 2024, Daniel's direct individual holding has decreased from 82.36k shares to 48.71k. There has only been one transaction (US$205k purchase) from insiders over the last 12 months. Announcement • Aug 10
Health Catalyst, Inc. (NasdaqGS:HCAT) acquired Lumeon Limited for $65 million. Health Catalyst, Inc. (NasdaqGS:HCAT) acquired Lumeon Limited for $65 million on August 8, 2024. Health Catalyst funded the transaction with a mix of stock and cash. Consideration includes approximately $37.5 million in cash and $2.5 million of our common stock, plus a potential recurring revenue-based earn-out of up to $25 million that, if achieved, would be paid solely in cash.
Health Catalyst, Inc. (NasdaqGS:HCAT) completed the acquisition of Lumeon Limited on August 8, 2024. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$37m net loss in 2 years). Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Reported Earnings • Aug 08
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: US$0.23 loss per share (improved from US$0.58 loss in 2Q 2023). Revenue: US$75.9m (up 3.7% from 2Q 2023). Net loss: US$13.5m (loss narrowed 59% from 2Q 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. 
